AG2R LA Mondiale Gestion D Actifs Invests $5.74 Million in Amgen Inc. $AMGN

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired a new position in Amgen Inc., purchasing 19,924 shares valued at approximately $5.74 million during the first quarter.
• Amgen recently reported earnings of $6.02 EPS, surpassing analyst estimates, with quarterly revenue of $9.18 billion up by 9.4% year-over-year.
• The company declared a quarterly dividend of $2.38, translating to an annualized dividend of $9.52 and a yield of 3.4% for stockholders of record.

AG2R LA Mondiale Gestion D Actifs acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 19,924 shares of the medical research company's stock, valued at approximately $5,742,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Vanguard Group Inc. increased its holdings in shares of Amgen by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 52,870,453 shares of the medical research company's stock worth $16,471,790,000 after acquiring an additional 148,658 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Amgen by 15.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,128,328 shares of the medical research company's stock worth $1,336,647,000 after acquiring an additional 685,785 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Amgen by 6.0% during the 1st quarter. Royal Bank of Canada now owns 4,883,134 shares of the medical research company's stock worth $1,521,339,000 after acquiring an additional 274,488 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Amgen by 5.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,454,164 shares of the medical research company's stock worth $1,387,695,000 after acquiring an additional 243,306 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after acquiring an additional 3,653,205 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. William Blair reissued an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. UBS Group decreased their target price on Amgen from $326.00 to $317.00 and set a "neutral" rating on the stock in a report on Wednesday, August 6th. Wall Street Zen lowered Amgen from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $305.00 price objective on shares of Amgen in a report on Tuesday, June 24th. Finally, Raymond James Financial assumed coverage on Amgen in a research report on Wednesday, September 3rd. They set a "market perform" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $304.43.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.69% of the company's stock.

Amgen Stock Performance

AMGN stock traded down $6.34 during trading hours on Friday, hitting $276.39. 2,143,109 shares of the stock were exchanged, compared to its average volume of 1,853,902. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The firm has a market capitalization of $148.80 billion, a P/E ratio of 22.60, a P/E/G ratio of 2.40 and a beta of 0.49. The company has a 50-day simple moving average of $292.54 and a two-hundred day simple moving average of $291.56. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen's dividend payout ratio is 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.